Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Neurocrine’s Tardive Dyskinesia Opportunity Could Support a Multi-Year Growth Runway

Neurocrine’s estimated 800,000-person tardive dyskinesia population could support years of prescription growth, but execution remains key.

Oct 25, 2026
Pharmaceutical

BioNTech and Bristol Myers Squibb Trial Data Put Oncology Pipelines in Focus

New lung cancer trial data from BioNTech and Bristol Myers Squibb shifts attention to pipeline quality, partnership economics and execution.

Oct 25, 2026
Pharmaceutical

AbbVie’s Skyrizi Expansion Gives Investors a New Test of Immunology Growth

A new subcutaneous induction option could strengthen Skyrizi’s role in AbbVie’s post-Humira strategy, though its financial impact remains un…

Oct 25, 2026
Pharmaceutical

Parabilis’ FDA Alignment Gives Its Desmoid Tumor Program a Clearer Road Map

Parabilis’ FDA-aligned dose strategy and placebo-controlled pivotal trial design may reduce uncertainty around its desmoid tumor program.

Oct 24, 2026
Pharmaceutical

Compass Therapeutics’ Tovecimig Data Published in Journal of Clinical Oncology

Peer-reviewed publication of Compass Therapeutics’ Phase 2/3 tovecimig study may shape investor sentiment ahead of regulatory next steps.

Oct 24, 2026
Pharmaceutical

Zymeworks’ ZW191 Posts Strong Response Rates in Platinum-Resistant Ovarian Cancer

ZW191 produced confirmed response rates of 64.5% and 55.3% in a difficult-to-treat ovarian cancer trial, sharpening focus on Zymeworks’ pipe…

Oct 24, 2026
Pharmaceutical

Teva's FDA Approval Adds a Fresh Catalyst for Healthcare Investors

Teva drew attention after an FDA approval, but its quoted price later stood at $40.21, down 1.009%, highlighting a mixed signal.

Oct 23, 2026
Pharmaceutical

Tango Therapeutics Slides 13% Despite 82% Pancreatic Cancer Response Rate

Tango Therapeutics fell 13% despite an 82% response rate, highlighting how traders discount small-sample pancreatic cancer data.

Oct 23, 2026
Pharmaceutical

Elicio’s Pancreatic Cancer Trial Misses Endpoint Despite Positive Subgroup Signal

Elicio’s Phase 2 pancreatic cancer trial missed its primary endpoint, while a subgroup signal raises questions rather than resolving camupep…

Oct 23, 2026
Pharmaceutical

IDEAYA’s IDE849 Data Put Dose, Safety and Pipeline Economics in Focus

IDE849’s Grade 3+ adverse-event rates rose from 5% to 22.2% across doses, sharpening questions about development strategy and IDYA’s pipelin…

Oct 23, 2026
Pharmaceutical

Rapport Director Buys Nearly $1 Million as Analyst Raises Price Target to $82

Insider buying and a higher $82 price target put Rapport Therapeutics’ clinical pipeline under the microscope.

Oct 23, 2026
Pharmaceutical

Biohaven Stock Jumps 25% After FDA Accepts Resubmitted Vyglxia Filing

BHVN jumped 25% after the FDA accepted Biohaven’s resubmitted Vyglxia filing, but acceptance is not final drug approval.

Oct 22, 2026